Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

© PCTU

Morszeck Service Unit für Preclinical Studies (PCTU)

Measuring different tumor parameters such as the micromilieu, metabolism, or biomarkers using non-invasional imaging techniques like positron emission tomography or magnetic resonance imaging (PET or MRI) can improve the concept of personalization and precision in medicine. These methods allow for the facilitation of patient stratification, risk assessment and adjustment during therapy. Biological tumor imaging before and during therapy is of utmost clinical importance, especially with regard to the biologically relevant information of tumor tissue. Thus, predictive imaging parameters can be established to predict and adapt the course of therapy. This results in a new innovative dimension of biological image-guided precision of radiotherapy.

The aim of the Morszeck PCTU is to test and establish novel radiotherapeutic treatment strategies in pre-clinical animal experiments and to complement clinical studies synergistically in order to better understand biological mechanisms determining clinical treatment parameters. Findings from clinical studies can be re-examined preclinically in detail in basic biological terms. In tandem with the extension of clinical applications in our Radiological and Radiooncological Research Center (REZ) for clinical trials and the core facility for small animal imaging, the PCTU provides the unique possibility of cooperation and translation of preclinical and clinical research in the field of radiation therapy. Thus, innovative studies combining radiotherapy with promising new drugs, immunotherapeutics and radiopharmaceuticals, which have an as yet unknown risk profile regarding their interaction with radiation, but are to be used together clinically in the future, can be tested preclinically.

Morszeck Service Unit für Preclinical Trials
© dkfz.de

Contact for Project Consulting and Experimental Design

© PCTU

The PCTU is happy to assist you with:

  • Project planning
  • Applications and amendments of animal approvals and third-party funding
  • Pilot/feasibility studies
  • Image-guided precision radiotherapy
  • Scientific evaluation of results
  • Support in writing reports and publications


If you are interested, please contact Dr. Mareike Roscher:

pctu@dkfz-heidelberg.de 

 

Our Team: Wahyu W. Hadiwikarta - Data Management, Mareike Roscher - Project Leader, Ina Kurth - Head of Division, Rosemarie Euler-Lange - Project Assistance

Our Team

© PCTU

to top
powered by webEdition CMS